{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:13:14Z","timestamp":1782814394190,"version":"3.54.5"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00134-024-07731-x","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T16:39:45Z","timestamp":1732639185000},"page":"235-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Personalizing beta-blockade in septic shock: finding the right rhythm and rate for the right patient"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1559-4078","authenticated-orcid":false,"given":"Franti\u0161ek","family":"Du\u0161ka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Rehberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"7731_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-024-07713-z","author":"M Balik","year":"2014","unstructured":"Balik M, Tavazzi G, Slama M (2014) Beta-blockers as antiarrhythmics in septic shock: a light at the end of the tunnel? Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-024-07713-z","journal-title":"Intensive Care Med"},{"issue":"9","key":"7731_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(20)30037-0","volume":"8","author":"Y Kakihana","year":"2020","unstructured":"Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, Nagano T, Morishima E, Matsuda N, J-Land 3S Study Group (2020) Efficacy and safety of landiolol, an ultra-short-acting \u03b21-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 8(9):863\u2013872. https:\/\/doi.org\/10.1016\/S2213-2600(20)30037-0. (Epub 2020 Mar 31 PMID: 32243865)","journal-title":"Lancet Respir Med"},{"issue":"17","key":"7731_CR3","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.2023.20134","volume":"330","author":"T Whitehouse","year":"2023","unstructured":"Whitehouse T, Hossain A, Perkins GD, Gordon AC, Bion J, Young D, McAuley D, Singer M, Lord J, Gates S, Veenith T, MacCallum NS, Yeung J, Innes R, Welters I, Boota N, Skilton E, Ghuman B, Hill M, Regan SE, Mistry D, Lall R, STRESS-L Collaborators (2023) Landiolol and organ failure in patients with septic shock: the STRESS-L randomized clinical trial. JAMA 330(17):1641\u20131652. https:\/\/doi.org\/10.1001\/jama.2023.20134. (PMID: 37877587 PMCID: PMC10600724)","journal-title":"JAMA"},{"issue":"10","key":"7731_CR4","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00134-024-07587-1","volume":"50","author":"S Rehberg","year":"2024","unstructured":"Rehberg S, Frank S, \u010cern\u00fd V, Cihl\u00e1\u0159 R, Borgstedt R, Biancofiore G, Guarracino F, Schober A, Trimmel H, Pernerstorfer T, Siebers C, Dost\u00e1l P, Morelli A, Joannidis M, Pretsch I, Fuchs C, Rahmel T, Podbregar M, Duliczki \u00c9, Tamme K, Unger M, Sus J, Klade C, Krejcy K, Kirchbaumer-Baroian N, Krumpl G, Du\u0161ka F, LANDI-SEP Study Group (2024) Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med 50(10):1622\u20131634. https:\/\/doi.org\/10.1007\/s00134-024-07587-1. (Epub 2024 Sep 19 PMID: 39297945; PMCID: PMC11447033)","journal-title":"Intensive Care Med"},{"issue":"2","key":"7731_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1164\/rccm.201603-0618OC","volume":"195","author":"PM Klein Klouwenberg","year":"2017","unstructured":"Klein Klouwenberg PM, Frencken JF, Kuipers S, Ong DS, Peelen LM, van Vught LA, Schultz MJ, van der Poll T, Bonten MJ, Cremer OL, MARS Consortium* (2017) Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis a cohort study. Am J Respir Crit Care Med 195(2):205\u2013211. https:\/\/doi.org\/10.1164\/rccm.201603-0618OC. (PMID: 27467907.#)","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"7731_CR6","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.ajem.2020.02.027","volume":"38","author":"M Arrigo","year":"2020","unstructured":"Arrigo M, Mebazaa A, Bettex D, Rudiger A (2020) Hemodynamic response of restoring sinus rhythm in critically ill patients with atrial fibrillation. Am J Emerg Med 38(6):1192\u20131194. https:\/\/doi.org\/10.1016\/j.ajem.2020.02.027. (Epub 2020 Feb 19 PMID: 32093960)","journal-title":"Am J Emerg Med"},{"issue":"4","key":"7731_CR7","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.chest.2020.10.049","volume":"159","author":"NA Bosch","year":"2021","unstructured":"Bosch NA, Rucci JM, Massaro JM, Winter MR, Quinn EK, Chon KH, McManus DD, Walkey AJ (2021) Comparative effectiveness of heart rate control medications for the treatment of sepsis-associated atrial fibrillation. Chest 159(4):1452\u20131459. https:\/\/doi.org\/10.1016\/j.chest.2020.10.049. (Epub 2020 Oct 24 PMID: 33619010 PMCID: PMC8039002)","journal-title":"Chest"},{"issue":"11","key":"7731_CR8","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00134-023-07208-3","volume":"49","author":"M Balik","year":"2023","unstructured":"Balik M, Maly M, Brozek T, Rulisek J, Porizka M, Sachl R, Otahal M, Brestovansky P, Svobodova E, Flaksa M, Stach Z, Horejsek J, Volny L, Jurisinova I, Novotny A, Trachta P, Kunstyr J, Kopecky P, Tencer T, Pazout J, Belohlavek J, Duska F, Krajcova A, Waldauf P (2023) Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial. Intensive Care Med 49(11):1283\u20131292. https:\/\/doi.org\/10.1007\/s00134-023-07208-3. (Epub 2023 Sep 12 PMID: 37698594)","journal-title":"Intensive Care Med"},{"issue":"5","key":"7731_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ehjacc\/zuae023","volume":"13","author":"P Waldauf","year":"2024","unstructured":"Waldauf P, Porizka M, Horejsek J, Otahal M, Svobodova E, Jurisinova I, Maly M, Brozek T, Rulisek J, Trachta P, Tencer T, Krajcova A, Duska F, Balik M (2024) The outcomes of patients with septic shock treated with propafenone compared to amiodarone for supraventricular arrhythmias are related to end-systolic left atrial volume. Eur Heart J Acute Cardiovasc Care 13(5):414\u2013422. https:\/\/doi.org\/10.1093\/ehjacc\/zuae023. (PMID: 38372622)","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"10","key":"7731_CR10","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.3390\/jcm13102951","volume":"13","author":"B Levy","year":"2024","unstructured":"Levy B, Slama M, Lakbar I, Maizel J, Kato H, Leone M, Okada M (2024) Landiolol for treatment of new-onset atrial fibrillation in critical care: a systematic review. J Clin Med 13(10):2951","journal-title":"J Clin Med"},{"key":"7731_CR11","doi-asserted-by":"publisher","first-page":"116676","DOI":"10.1016\/j.taap.2023.116676","volume":"477","author":"A Kraj\u010dov\u00e1","year":"2023","unstructured":"Kraj\u010dov\u00e1 A, N\u011bmcov\u00e1 V, Hala\u010dov\u00e1 M, Waldauf P, Bal\u00edk M, Du\u0161ka F (2023) Amiodarone but not propafenone impairs bioenergetics and autophagy of human myocardial cells. Toxicol Appl Pharmacol 477:116676. https:\/\/doi.org\/10.1016\/j.taap.2023.116676. (Epub 2023 Sep 3 PMID: 37661063)","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-024-07731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-024-07731-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-024-07731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:44:43Z","timestamp":1738417483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-024-07731-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7731"],"URL":"https:\/\/doi.org\/10.1007\/s00134-024-07731-x","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"12 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. FD and SR were involved by LANDI\u2013SEP trial, sponsored by AOP Orphan Pharmaceuticals GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}